207 related articles for article (PubMed ID: 19492145)
1. Future of oral antiplatelet therapy: four challenged hypotheses.
Serebruany VL; Makarov LM
Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
[No Abstract] [Full Text] [Related]
2. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
[No Abstract] [Full Text] [Related]
3. The TRITON versus PLATO trials: differences beyond platelet inhibition.
Serebruany VL
Thromb Haemost; 2010 Feb; 103(2):259-61. PubMed ID: 20024505
[TBL] [Abstract][Full Text] [Related]
4. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
Alban S
Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
[No Abstract] [Full Text] [Related]
5. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel.
Wiviott SD; Antman EM; Braunwald E
Circulation; 2010 Jul; 122(4):394-403. PubMed ID: 20660815
[No Abstract] [Full Text] [Related]
7. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
8. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
9. [Pharmazie in unserer Zeit 4/2009].
Alban S; Dingermann T
Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
[No Abstract] [Full Text] [Related]
10. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
[TBL] [Abstract][Full Text] [Related]
12. [Do genetic factors reduce the effects of clopidogrel?].
Scharf RE
Dtsch Med Wochenschr; 2011 Apr; 136(15):786. PubMed ID: 21469049
[No Abstract] [Full Text] [Related]
13. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Mariani M; Mariani G; De Servi S
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
[TBL] [Abstract][Full Text] [Related]
15. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Oprea AD; Popescu WM
J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
[No Abstract] [Full Text] [Related]
16. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
Kern MJ
Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
[No Abstract] [Full Text] [Related]
17. Test before you stop.
Kumar A; Roberts DH
Arch Surg; 2009 Aug; 144(8):787; author reply 787. PubMed ID: 19687387
[No Abstract] [Full Text] [Related]
18. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
Tomasello SD; Tello-Montoliu A; Angiolillo DJ
Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
[TBL] [Abstract][Full Text] [Related]
19. For better or for worse: the future of antiplatelet therapy.
Alvarez W
Am J Health Syst Pharm; 2008 Jun; 65(11):1017. PubMed ID: 18499873
[No Abstract] [Full Text] [Related]
20. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
